MARKET

MRNS

MRNS

Marinus Pharmace
NASDAQ
10.02
+0.03
+0.30%
Opening 14:45 02/27 EST
OPEN
10.10
PREV CLOSE
9.99
HIGH
10.12
LOW
9.87
VOLUME
225.75K
TURNOVER
0
52 WEEK HIGH
11.26
52 WEEK LOW
5.57
MARKET CAP
546.83M
P/E (TTM)
-3.7890
1D
5D
1M
3M
1Y
5Y
Marinus (MRNS) Receives a Buy from RBC Capital
TipRanks · 1d ago
Weekly Report: what happened at MRNS last week (0219-0223)?
Weekly Report · 1d ago
Marinus Pharmace: Statement of changes in beneficial ownership of securities
Press release · 5d ago
Weekly Report: what happened at MRNS last week (0212-0216)?
Weekly Report · 02/19 12:34
Weekly Report: what happened at MRNS last week (0205-0209)?
Weekly Report · 02/12 12:19
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
NASDAQ · 02/06 11:19
Weekly Report: what happened at MRNS last week (0129-0202)?
Weekly Report · 02/05 12:32
Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment
TipRanks · 01/30 22:13
More
About MRNS
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of therapeutics for seizure disorders. The Company’s commercial product, ZTALMY (ganaxolone) oral suspension CV, has been approved by the United States Food and Drug Administration (FDA) for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The Company's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. Its ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Webull offers Marinus Pharmaceuticals Inc stock information, including NASDAQ: MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRNS stock methods without spending real money on the virtual paper trading platform.